SI-BONE (SIBN) Projected to Post Quarterly Earnings on Monday

SI-BONE (NASDAQ:SIBN) is projected to release its earnings data after the market closes on Monday, February 24th. Analysts expect SI-BONE to post earnings of ($0.16) per share and revenue of $48.87 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

SI-BONE Trading Down 0.9 %

NASDAQ SIBN opened at $17.84 on Friday. The firm’s fifty day moving average price is $15.65 and its 200 day moving average price is $14.66. SI-BONE has a 12 month low of $11.70 and a 12 month high of $20.74. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The company has a market capitalization of $748.21 million, a price-to-earnings ratio of -19.39 and a beta of 1.17.

Insiders Place Their Bets

In other SI-BONE news, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the transaction, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total value of $51,013.00. Following the sale, the insider now directly owns 222,814 shares of the company’s stock, valued at $3,097,114.60. The trade was a 1.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,311 shares of company stock valued at $130,356. Insiders own 3.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SIBN. Truist Financial raised their price objective on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a research report on Monday, January 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $23.00.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.